Next Article in Journal
Role of Trientine in Hypertrophic Cardiomyopathy: A Review of Mechanistic Aspects
Previous Article in Journal
Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism—From Modern Recommendations to Clinical Application
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 9
10.3390/ph15091147
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Montelukast and Acute Coronary Syndrome: The Endowed Drug

by
Basil Mohammed Alomair
1,†,
Hayder M. Al-kuraishy
2,†,
Ali I. Al-Gareeb
2,
Sadiq M. Al-Hamash
2,
Michel De Waard
3,4,5,
Jean-Marc Sabatier
6,
Hebatallah M. Saad
7,* and
Gaber El-Saber Batiha
8,*
1
Internal Medicine, Endocrinology and Diabetes, Department of Medicine, College of Medicine, Aljouf University, Sakaka 72388, Saudi Arabia
2
Department of Pharmacology and Toxicology, College of Medicine, Al-Mustansiriyah University, Baghdad P.O. Box 14132, Iraq
3
Smartox Biotechnology, 6 Rue des Platanes, 38120 Saint-Egrève, France
4
L’institut du Thorax, INSERM, CNRS, Université de Nantes, 44007 Nantes, France
5
LabEx «Ion Channels, Science & Therapeutics», Université de Nice Sophia-Antipolis, 06560 Valbonne, France
6
Institut de Neurophysiopathologie (INP), Faculté des Sciences Médicales et Paramédicales, Aix-Marseille Université, CNRS UMR 7051, 27 Bd Jean Moulin, 13005 Marseille, France
7
Department of Pathology, Faculty of Veterinary Medicine, Matrouh University, Marsa Matruh 51744, Egypt
8
Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Egypt
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2022, 15(9), 1147; https://doi.org/10.3390/ph15091147
Submission received: 18 August 2022 / Revised: 6 September 2022 / Accepted: 9 September 2022 / Published: 14 September 2022
(This article belongs to the Section Pharmacology)
Browse Figures
Versions Notes

Abstract

Acute coronary syndrome (ACS) is a set of signs and symptoms caused by a reduction of coronary blood flow with subsequent myocardial ischemia. ACS is associated with activation of the leukotriene (LT) pathway with subsequent releases of various LTs, including LTB4, LTC4, and LTD4, which cause inflammatory changes and induction of immunothrombosis. LTs through cysteine leukotriene (CysLT) induce activation of platelets and clotting factors with succeeding coronary thrombosis. CysLT receptor (CysLTR) antagonists such as montelukast (MK) may reduce the risk of the development of ACS and associated complications through suppression of the activation of platelet and clotting factors. Thus, this critical review aimed to elucidate the possible protective role of MK in the management of ACS. The LT pathway is implicated in the pathogenesis of atherosclerosis, cardiac hypertrophy, and heart failure. Inhibition of the LT pathway and CysL1TR by MK might be effective in preventing cardiovascular complications. MK could be an effective novel therapy in the management of ACS through inhibition of pro-inflammatory CysLT1R and modulation of inflammatory signaling pathways. MK can attenuate thrombotic events by inhibiting platelet activation and clotting factors that are activated during the development of ACS. In conclusion, MK could be an effective agent in reducing the severity of ACS and associated complications. Experimental, preclinical, and clinical studies are recommended to confirm the potential therapeutic of MK in the management of ACS.
Keywords: acute coronary syndrome; leukotriene; montelukast; antileukotrienes therapy acute coronary syndrome; leukotriene; montelukast; antileukotrienes therapy
Graphical Abstract

Share and Cite

MDPI and ACS Style

Alomair, B.M.; Al-kuraishy, H.M.; Al-Gareeb, A.I.; Al-Hamash, S.M.; De Waard, M.; Sabatier, J.-M.; Saad, H.M.; El-Saber Batiha, G. Montelukast and Acute Coronary Syndrome: The Endowed Drug. Pharmaceuticals 2022, 15, 1147. https://doi.org/10.3390/ph15091147

AMA Style

Alomair BM, Al-kuraishy HM, Al-Gareeb AI, Al-Hamash SM, De Waard M, Sabatier J-M, Saad HM, El-Saber Batiha G. Montelukast and Acute Coronary Syndrome: The Endowed Drug. Pharmaceuticals. 2022; 15(9):1147. https://doi.org/10.3390/ph15091147

Chicago/Turabian Style

Alomair, Basil Mohammed, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Sadiq M. Al-Hamash, Michel De Waard, Jean-Marc Sabatier, Hebatallah M. Saad, and Gaber El-Saber Batiha. 2022. "Montelukast and Acute Coronary Syndrome: The Endowed Drug" Pharmaceuticals 15, no. 9: 1147. https://doi.org/10.3390/ph15091147

APA Style

Alomair, B. M., Al-kuraishy, H. M., Al-Gareeb, A. I., Al-Hamash, S. M., De Waard, M., Sabatier, J.-M., Saad, H. M., & El-Saber Batiha, G. (2022). Montelukast and Acute Coronary Syndrome: The Endowed Drug. Pharmaceuticals, 15(9), 1147. https://doi.org/10.3390/ph15091147

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop